Core Insights - Clearmind Medicine is advancing its proprietary compound MEAI, a non-hallucinogenic neuroplastogen, as a potential next-generation treatment for obesity, targeting the psychological roots of eating behaviors [1] - The obesity treatment market is projected to exceed $100 billion, indicating significant growth potential for innovative therapies like MEAI [1] Company Overview - Clearmind Medicine is a clinical-stage biotech company focused on developing novel therapeutics to address under-treated health issues, particularly obesity [1] - MEAI is designed to disrupt rigid behavioral patterns, promote cognitive flexibility, and enhance neuronal plasticity while providing metabolic benefits [1] Mechanism of Action - Unlike GLP-1-based treatments that primarily target gut hormones, MEAI works directly in the brain by modulating the monoaminergic system, addressing compulsive eating behaviors and food addiction [1] - Pre-clinical studies indicate that MEAI can modulate energy balance, boost fat burning, improve insulin sensitivity, and significantly decrease fat mass while preserving lean muscle mass [1] Comparative Analysis - MEAI shows a potential weight loss profile of approximately 20% reduction in pre-clinical studies, prioritizing fat loss and muscle preservation, compared to GLP-1 drugs which show a 15-22% reduction often accompanied by muscle loss [1] - MEAI has a favorable safety profile with no reported sedation or hyperactivity, contrasting with common gastrointestinal issues associated with GLP-1 drugs [1] Strategic Developments - Clearmind has filed new patent applications targeting obesity and metabolic disorders and is collaborating with Polyrizon to develop an intranasal formulation for enhanced delivery [1] - The company is progressing in its FDA-approved Phase I/IIa trial for alcohol use disorder, with successful cohort completions and upcoming data readouts [1] Future Outlook - Clearmind's leadership emphasizes MEAI's potential as a safer, more effective alternative to current therapies, focusing on behavioral aspects of obesity that hormonal drugs often overlook [1] - The combination of pre-clinical and clinical evidence, intellectual property advancements, and strategic partnerships positions MEAI as a promising solution for sustainable weight management [1]

Core Viewpoint - Polyrizon Ltd. has entered into a development agreement with Clearmind Medicine Inc. to leverage Polyrizon's intranasal delivery platform for the clinical development of Clearmind's drug candidate MEAI, aimed at treating addiction-related and other CNS conditions [1][2][3] Group 1: Collaboration Details - The collaboration aims to advance an intranasal formulation of MEAI to support Clearmind's future clinical development programs [2] - Polyrizon's proprietary intranasal technology is designed to enable targeted and efficient delivery of drugs, potentially offering significant value in Clearmind's clinical pathway [3] Group 2: Polyrizon's Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The company's Capture and Contain TM hydrogel technology is designed to enhance bioadhesion and prolong retention at the nasal site for drug delivery [4][6] Group 3: Clearmind's Focus - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address underserved health issues, including alcohol use disorder [7] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [8]

Core Insights - Clearmind Medicine Inc. has made significant progress in 2025, particularly in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD) [1][2] Clinical Trial Progress - Clearmind advanced its multinational Phase I/IIa clinical trial for CMND-100, with site activations at prestigious institutions such as Yale School of Medicine and Johns Hopkins University [3] - The company successfully initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events [3] - Enrollment and dosing for the second cohort were completed, accelerating the path toward further data readouts [3] Independent Safety Endorsement - Clearmind received unanimous approval from the Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa clinical trial following an interim review, reinforcing CMND-100's favorable safety profile [4] Global Footprint Expansion - The company strengthened its intellectual property portfolio with multiple international patent filings and publications targeting various health indications, including weight loss, obesity, and mental health disorders [5] Leadership Commentary - The CEO of Clearmind highlighted 2025 as a pivotal year for the company, emphasizing its transition into a clinical-stage entity and commitment to delivering transformative treatments for addictions and mental health challenges [6] Intellectual Property Portfolio - Clearmind's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [8]

Core Insights - Planet Labs PBC reported third-quarter revenue of $81.25 million, exceeding analyst expectations of $71.99 million, leading to a significant rise in share price [1][2] - The company also provided fourth-quarter sales guidance above estimates and raised its FY26 sales guidance, indicating positive growth prospects [1][2] Financial Performance - Third-quarter revenue: $81.25 million, surpassing estimates by approximately 12.5% [2] - Adjusted earnings per share were breakeven, while GAAP earnings showed a loss of $0.19 per share [2] Market Reaction - Planet Labs PBC shares increased by 16.4%, reaching $15.15 in pre-market trading following the earnings report [2]

Core Viewpoint - Clearmind Medicine Inc. is implementing a 1-for-40 reverse stock split to comply with Nasdaq's minimum bid price requirement, following a significant decline in its stock price and market capitalization [2][4]. Group 1: Stock Performance - Clearmind Medicine shares fell 29.92% in after-hours trading, closing at $0.0801, down 6.08% on the day [1]. - The stock has experienced a 91.41% decline over the past year, with a market capitalization of $6.86 million [5]. Group 2: Reverse Stock Split Details - The reverse stock split will reduce the outstanding common shares from 59.99 million to 1.50 million, effective December 15 [3]. - The company's authorized share capital will remain unchanged, and no fractional shares will be issued, with all fractions rounded up to the nearest whole share [3]. Group 3: Board Approval and Adjustments - The board of directors approved the reverse split on November 12, in accordance with the company's articles of association [4]. - A proportionate adjustment will be made to the per-share exercise price and the number of shares issuable upon exercise of all outstanding options and warrants [4].

Core Insights - Clearmind Medicine Inc. (NASDAQ:CMND) experienced a 7.09% increase in pre-market trading, reaching a price of $0.1713 after closing at $0.16, which was a decline of 19.4% on the previous day [1][6]. Group 1: Clinical Trial Developments - The company announced that Tel Aviv Sourasky Medical Center (TASMC) has enrolled the first participant in its multinational Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, which has received approval from the U.S. Food and Drug Administration [2]. - TASMC is part of an expanded trial network that includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center for patient screening and enrollment [3]. - The Phase I/IIa trial is designed to assess the pharmacokinetics, safety, tolerability, and initial efficacy of CMND-100, an oral MEAI-based medication that is not hallucinogenic, with the first cohort's top-line results indicating no significant adverse events [5]. Group 2: Executive Commentary and Stock Performance - Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated that the recruitment of the first patient at TASMC is a significant step that accelerates the global trial [6]. - The company's stock has seen a substantial decline of 88.97% year-to-date, with a 52-week price range of $0.15 to $2.18 and a market capitalization of $5.26 million [6].

Core Viewpoint - SciSparc Ltd. has announced an advancement in its collaboration with NeuroThera Labs Inc. by filing a patent application for a novel combination therapy targeting depression, which involves 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] Group 1: Collaboration and Patent Filing - The patent application is a result of the ongoing collaboration between Neurothera and Clearmind Medicine Inc., focusing on a therapy for depression using MEAI and PEA [2][3] - This new filing expands the joint intellectual property portfolio, with a total of 13 patents filed through the collaboration, addressing various conditions including alcohol use disorder, cocaine addiction, obesity, and depression [3] Group 2: Market Context and Impact - According to the World Health Organization, approximately 332 million people globally suffer from major depressive disorder, representing about 5.7% of adults, with higher prevalence in women (6.9%) compared to men (4.6%) [2] - Depression remains one of the leading causes of disability worldwide, significantly contributing to the global burden of disease [2] Group 3: Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments through its majority-owned subsidiary Neurothera Labs Inc., which is engaged in developing cannabinoid-based therapeutics [4] - The company is involved in various drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [4][5]

Core Insights - Clearmind Medicine Inc. has initiated its FDA-approved Phase I/IIa clinical trial for CMND-100 at Hadassah Medical Center, expanding the trial's reach and emphasizing the potential of this non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD) [1][2] Group 1: Clinical Trial Details - The multinational study aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - Hadassah Medical Center was added as a clinical site for the ongoing trial, which was activated swiftly following final approval earlier in the month [2] Group 2: Early Findings - Top-line data from the first cohort of the clinical trial indicated a favorable safety profile, with no serious adverse events reported and high adherence to the dosing regimen [3] - These early findings support the ongoing evaluation of CMND-100 as a potential breakthrough therapy for AUD, a condition affecting millions globally [3] Group 3: Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company's intellectual portfolio includes nineteen patent families with 31 granted patents, and it plans to seek additional patents as warranted [5]

Core Insights - Neurothera Labs Inc. announced that Clearmind Medicine Inc. has filed an Israeli patent application for a combination therapy targeting depression, utilizing 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] - The collaboration between Neurothera and Clearmind aims to address the significant global issue of major depressive disorder, which affects over 280 million people and is a leading cause of disability [2] Company Overview - Neurothera Labs Inc. is a clinical-stage biotech company focused on developing innovative therapeutics for central nervous system disorders and other underserved health conditions through collaborations [4] Intellectual Property Development - The recent patent application expands the joint intellectual property portfolio, which now includes 13 patents related to MEAI and N-Acylethanolamines for various conditions, including depression, alcohol use disorder, cocaine addiction, and obesity [3]

Group 1: LightPath Technologies Inc - LightPath Technologies Inc (NASDAQ:LPTH) reported better-than-expected first-quarter financial results, leading to a sharp rise in its shares during pre-market trading [1] - The company reported a quarterly loss of 7 cents per share, which was better than the analyst estimate of a 9-cent loss [1] - Quarterly revenue for LightPath Technologies was $15.05 million, surpassing the consensus estimate of $12.66 million [1] - Following the financial results, shares of LightPath Technologies jumped 6.8% to $8.58 in pre-market trading [1] Group 2: Other Stocks in Pre-Market Trading - Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) surged 170% to $2.65 after releasing pricing details for its underwritten public offering [6] - Kandal M Venture Limited (NASDAQ:FMFC) gained 70.4% to $0.9490 after previously falling 8% [6] - Amaze Holdings, Inc. (NYSE:AMZE) rose 68.4% to $0.8934 after extending its partnership with Adobe Express [6] - VCI Global Limited (NASDAQ:VCIG) surged 44.4% to $1.88 after a 27% dip on Tuesday [6] - Clearmind Medicine Inc. (NASDAQ:CMND) gained 27% to $0.5830 after a 32% decline on Tuesday [6] - Lucyd, Inc (NASDAQ:LUCY) surged 23.3% to $1.90 [6] - BILL Holdings, Inc (NYSE:BILL) gained 14.8% to $53.49 [6] - Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) gained 11.7% to $0.8160 after a 5% decline [6] - DBV Technologies SA – ADR (NASDAQ:DBVT) rose 8.7% to $14.50, confirming completion of Phase 3 treatment phase for VIASKIN peanut patch [6] Group 3: Decliners in Pre-Market Trading - MSP Recovery Inc (NASDAQ:MSPR) tumbled 18.2% to $0.46 after a 75% jump on Tuesday [6] - Aspire Biopharma Holdings Inc (NASDAQ:ASBP) declined 16.5% to $0.097 after a 25% dip [6] - Rain Enhancement Technologies Holdco Inc (NASDAQ:RAIN) fell 14.3% to $4.66 after a 10% gain [6] - IRIDEX Corp (NASDAQ:IRIX) shares dipped 13.4% to $1.03 following the announcement of quarterly results [6] - Leifras Co Ltd (NASDAQ:LFS) fell 13.4% to $9.82 after a significant 577% jump on Tuesday [6] - Graphjet Technology (NASDAQ:GTI) fell 12.3% to $3.40 after an 8% decline [6] - ICZOOM Group Inc (NASDAQ:IZM) fell 10.1% to $1.25 after a 34% gain [6] - Biohaven Ltd (NYSE:BHVN) dipped 7.7% to $7.86 after announcing a $150 million offering [6] - Stitch Fix Inc (NASDAQ:SFIX) dipped 4% to $4.21 [6] - Daqo New Energy Corp (NYSE:DQ) fell 3.7% to $34.29 [6]